254. ポルフィリン症 Disease details / Clinical trials / Drug dev / DR info

5-probe cocktail
   Alnylam Pharmaceuticals
      2018   Phase 1   NCT03505853   Sweden
A novel synthetic, orally-administered, NON-peptide small molecule, which acts AS
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 3   EUCTR2019-004226-16-IT   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
Afamelanotide
   Clinuvel Pharmaceuticals Limited
      2012   Phase 3   NCT01605136   United States
      2011   Phase 3   NCT04578496   -
      2010   Phase 2   NCT01097044   United States
      2010   -   EUCTR2009-011018-51-IE   Finland;Ireland;Netherlands;United Kingdom
      2009   Phase 3   NCT00979745   Finland;France;Germany;Ireland;Netherlands;United Kingdom
      2009   -   EUCTR2009-011018-51-NL   Finland;Ireland;Netherlands;United Kingdom
      2009   -   EUCTR2009-011018-51-GB   Finland;Ireland;Netherlands;United Kingdom
      2009   -   EUCTR2009-011018-51-FI   Finland;Ireland;Netherlands;United Kingdom
      2007   Phase 3   NCT04053270   -
Afamelanotide 16 MG
   Clinuvel Pharmaceuticals Limited
      2023   Phase 2   NCT05854784   Netherlands
Afamelanotide 16MG implant
   Clinuvel Europe Limited
      2024   Phase 1/Phase 2   NCT06388642   Belgium;Netherlands
Afamelanotide implant
   Clinuvel Pharmaceuticals Limited
      -   -   EUCTR2007-000636-13-DE   France;Germany;Italy;Netherlands;Sweden;United Kingdom
ALN-60519
   ALNYLAM PHARMACEUTICALS, INC.
      2018   Phase 3   EUCTR2017-002432-17-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-002432-17-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-FI   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-SE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-DK   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 1;Phase 2   EUCTR2016-002638-54-SE   Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2   EUCTR2016-002638-54-GB   Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-002432-17-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2017-002432-17-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
ALN-AS1
   ALNYLAM PHARMACEUTICALS, INC.
      2018   Phase 3   EUCTR2017-002432-17-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals
      2015   Phase 1   NCT02452372   Sweden;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-002432-17-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-FI   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-SE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-DK   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 1;Phase 2   EUCTR2016-002638-54-SE   Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2   EUCTR2016-002638-54-GB   Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-002432-17-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2017-002432-17-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Chlorpromazine hydrochloride
   Cycle Pharmaceuticals Ltd.
      2016   Phase 1   NCT02943213   South Africa
Cimetidine
   Amy K. Dickey, M.D.
      2022   Phase 2   NCT05020184   United States
Colestipol
   Brigham and Women's Hospital
      2011   Phase 2/Phase 3   NCT01422915   United States
Colestyramine
   Guy's & St Thomas' NHS Foundation Trust
      2007   Phase 4   EUCTR2007-002863-28-GB   United Kingdom
CUV1647
   CLINUVEL PHARMACUETICALS LTD
      2007   -   EUCTR2007-000636-13-IT   France;Germany;Italy;Netherlands;Sweden;United Kingdom
   Clinuvel Pharmaceuticals Limited
      2010   -   EUCTR2009-011018-51-IE   Finland;Ireland;Netherlands;United Kingdom
      2009   -   EUCTR2009-011018-51-NL   Finland;Ireland;Netherlands;United Kingdom
      2009   -   EUCTR2009-011018-51-GB   Finland;Ireland;Netherlands;United Kingdom
      2009   -   EUCTR2009-011018-51-FI   Finland;Ireland;Netherlands;United Kingdom
      2008   -   EUCTR2007-000636-13-SE   France;Germany;Italy;Netherlands;Sweden;United Kingdom
      2008   -   EUCTR2007-000636-13-NL   France;Germany;Italy;Netherlands;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000636-13-GB   France;Germany;Italy;Netherlands;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-000636-13-FR   France;Germany;Italy;Netherlands;Sweden;United Kingdom
      -   -   EUCTR2007-000636-13-DE   France;Germany;Italy;Netherlands;Sweden;United Kingdom
Cysteine hydrochloride
   Brigham and Women's Hospital
      1996   Phase 3   NCT00004940   -
   FDA Office of Orphan Products Development
      1996   -   NCT00004831   -
Deferasirox
   University of Texas Southwestern Medical Center
      2008   Phase 3   NCT00599326   United States
Dersimelagon
   Mitsubishi Tanabe Development America Inc.
      2022   Phase 3   EUCTR2021-001831-17-IT   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004226-16-IT   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
   Mitsubishi Tanabe Pharma America Inc.
      2023   Phase 3   NCT06144840   Australia;Bulgaria;Czechia;France;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   Mitsubishi Tanabe Pharma America, Inc.
      2022   Phase 3   EUCTR2021-001831-17-NO   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2022   Phase 3   EUCTR2021-001831-17-ES   Canada;Germany;Japan;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001831-17-DE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004226-16-FI   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004226-16-DE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004226-16-SE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004226-16-GB   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2019-004226-16-NO   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America, Inc.
      -   Phase 3   EUCTR2021-001831-17-SE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
DISC-1459
   Disc Medicine, Inc
      2025   Phase 3   NCT06910358   United States
      2023   Phase 2/Phase 3   NCT05883748   Australia;United States
      2022   Phase 2   NCT05308472   United States
Dosage OF delta-aminolevulinic acid and porphobilinogen
   Association pour la Recherche en Medecine Interne
      2021   -   NCT04923516   -
Exjade
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2   NCT01284946   France
Givosiran
   ALNYLAM PHARMACEUTICALS, INC.
      2018   Phase 3   EUCTR2017-002432-17-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals
      2020   -   NCT04056481   Australia;Belgium;Canada;France;Germany;Luxembourg;Netherlands;Spain;Sweden;United States
      2018   Phase 1   NCT03505853   Sweden
      2017   Phase 3   NCT03338816   Australia;Belgium;Bulgaria;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2016   Phase 1/Phase 2   NCT02949830   Sweden;United Kingdom;United States
      2015   Phase 1   NCT02452372   Sweden;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-002432-17-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-FI   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002432-17-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-SE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-DK   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2017-002432-17-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      2017   Phase 1;Phase 2   EUCTR2016-002638-54-SE   Sweden;United Kingdom;United States
      2016   Phase 1;Phase 2   EUCTR2016-002638-54-GB   Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-002432-17-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2017-002432-17-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Fujii Norihisa
      2021   -   JPRN-jRCT2071200074   -
Glucose
   The University of Texas Medical Branch, Galveston
      2014   Phase 2   NCT02180412   United States
Heme arginate
   National Center for Research Resources (NCRR)
      1998   Phase 1   NCT00004398   -
      1998   Phase 1   NCT00004397   -
      1997   Phase 2   NCT00004396   United States
      1993   Phase 1/Phase 2   NCT00004789   -
Hemin
   The University of Texas Medical Branch, Galveston
      2014   -   NCT02935400   United States
Hemin FOR injection
   The University of Texas Medical Branch, Galveston
      2015   Phase 2   NCT02922413   United States
Hydroxychloroquine
   The University of Texas Medical Branch, Galveston
      2006   Phase 2   NCT01573754   United States
Isoniazid
   University of Utah
      2012   -   NCT01550705   United States
Luteinizing hormone-releasing factor
   National Center for Research Resources (NCRR)
      1987   -   NCT00004330   United States
MT-7117
   Mitsubishi Tanabe Development America Inc.
      2022   Phase 3   EUCTR2021-001831-17-IT   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004226-16-IT   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
   Mitsubishi Tanabe Pharma America, Inc.
      2022   Phase 3   EUCTR2021-001831-17-NO   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2022   Phase 3   EUCTR2021-001831-17-ES   Canada;Germany;Japan;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001831-17-DE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004226-16-FI   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004226-16-DE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004226-16-SE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004226-16-GB   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2019-004226-16-NO   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
   Mitsubishi Tanabe Pharma Development America, Inc.
      -   Phase 3   EUCTR2021-001831-17-SE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
MT-7117 high dose
   Mitsubishi Tanabe Pharma America Inc.
      2020   Phase 3   NCT04402489   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   NCT03520036   United States
MT-7117 LOW dose
   Mitsubishi Tanabe Pharma America Inc.
      2020   Phase 3   NCT04402489   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   NCT03520036   United States
NLE4-D-PHE7-alpha-MSH
   CLINUVEL PHARMACUETICALS LTD
      2007   -   EUCTR2007-000636-13-IT   France;Germany;Italy;Netherlands;Sweden;United Kingdom
Oral iron
   Icahn School of Medicine at Mount Sinai
      2016   -   NCT02979249   United States
Panhematin
   The University of Texas Medical Branch, Galveston
      2014   Phase 2   NCT02180412   United States
Phlebotomy
   The University of Texas Medical Branch, Galveston
      2006   Phase 2   NCT01573754   United States
Porphozym
   Zymenex A/S
      2003   Phase 2/Phase 3   NCT00418795   United States
PORT-77
   Portal Therapeutics, Inc.
      2025   Phase 2   NCT06971900   United States
Questran
   Guy's & St Thomas' NHS Foundation Trust
      2007   Phase 4   EUCTR2007-002863-28-GB   United Kingdom
RAAV2/5-pbgd vector dosage 1
   Digna Biotech S.L.
      2012   Phase 1   NCT02082860   Spain
RAAV2/5-pbgd vector dosage 2
   Digna Biotech S.L.
      2012   Phase 1   NCT02082860   Spain
RAAV2/5-pbgd vector dosage 3
   Digna Biotech S.L.
      2012   Phase 1   NCT02082860   Spain
RAAV2/5-pbgd vector dosage 4
   Digna Biotech S.L.
      2012   Phase 1   NCT02082860   Spain
Recombinant human porphobilinogen deaminase
   Zymenex A/S
      2003   Phase 2/Phase 3   NCT00418795   United States
Scenesse
   CLINUVEL (UK) LTD
      2022   Phase 2   EUCTR2018-004164-60-NL   Netherlands;Switzerland
   Clinuvel Pharmaceuticals Limited
      2009   -   EUCTR2009-011018-51-GB   Finland;Ireland;Netherlands;United Kingdom
TIN mesoporphyrin
   National Center for Research Resources (NCRR)
      1998   Phase 1   NCT00004398   -
      1998   Phase 1   NCT00004397   -
      1997   Phase 2   NCT00004396   United States
      1993   Phase 1/Phase 2   NCT00004789   -